Track Talphera, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Talphera, Inc. TLPH · Stock Open Talphera, Inc. in new tab

0.9060 USD
EPS
-0.26
P/B
3.72
ROE
-143.36
Beta
0.73
Target Price
3.13 USD
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
EPS-0.26
Book Value0.28
Price to Book3.72
Debt/Equity45.11
% Insiders21.413%
Estimates
Forward P/E-4.63
Forward EPS-0.22
Target Mean Price3.13

DCF valuation

Model fair value for Talphera, Inc. (TLPH)
Result
Sign in to run the valuation for TLPH.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus None · mean target 3.13 USD (low 3.00, high 3.50) · as of 13 Nov 2026
Low 3.00
Mean 3.13
High 3.50
Price 0.9060
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Talphera, Inc. Logo Talphera, Inc. Analysis (TLPH)

US Healthcare Official Website Stock

Is Talphera, Inc. a good investment? Talphera, Inc. (TLPH) is currently trading at 0.9060 USD. Market analysts have a consensus price target of 3.13 USD. This suggests a potential upside from current levels.

Earnings Schedule: Talphera, Inc. is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is -0.22.

Investor FAQ

Does Talphera, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Talphera, Inc.?

Talphera, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of -0.26.

Company Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Exchange Ticker
NGM (Sweden) ACRX
FRA (Germany) R5X.F
NASDAQ TLPH
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Oct. 26, 2022 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion